Negative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast Carcinoma

ABSTRACT A drastic reduction in BRCA1 gene expression is a characteristic feature of aggressive sporadic breast carcinoma. However, the mechanisms underlying BRCA1 downregulation in breast cancer are not well understood. Here we report that both in vitro and in vivo HMGA1b protein binds to and inhibits the activity of both human and mouse BRCA1 promoters. Consistently, murine embryonic stem (ES) cells with the Hmga1 gene deleted display higher Brca1 mRNA and protein levels than do wild-type ES cells. Stable transfection of MCF-7 cells with the HMGA1b cDNA results in a decrease of BRCA1 gene expression and in a lack of BRCA1 induction after estrogen treatment. Finally, we found an inverse correlation between HMGA1 and BRCA1 mRNA and protein expression in human mammary carcinoma cell lines and tissues. These data indicate that HMGA1 proteins are involved in transcriptional regulation of the BRCA1 gene, and their overexpression may have a role in BRCA1 downregulation observed in aggressive mammary carcinomas.

[1]  G. Viglietto,et al.  Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. , 2018, Cancer research.

[2]  J. Ford,et al.  BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2002, Nature Genetics.

[3]  T. Waldmann,et al.  Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Reeves,et al.  HMGI/Y proteins: flexible regulators of transcription and chromatin structure. , 2001, Biochimica et biophysica acta.

[5]  M. Erdos,et al.  Role of direct interaction in BRCA1 inhibition of estrogen receptor activity , 2001, Oncogene.

[6]  R. Reeves,et al.  Architectural Transcription Factor HMGI(Y) Promotes Tumor Progression and Mesenchymal Transition of Human Epithelial Cells , 2001, Molecular and Cellular Biology.

[7]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[8]  V. Jordan,et al.  Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  L. Hilakivi-Clarke.  Estrogens, BRCA1, and breast cancer. , 2000, Cancer research.

[10]  I. Andrulis,et al.  Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. , 2000, Carcinogenesis.

[11]  P. Pharoah,et al.  Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers , 2000, International journal of cancer.

[12]  Y. Atomi,et al.  Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. , 2000, Cancer research.

[13]  G. Chiappetta,et al.  Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  V. Orlando,et al.  Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-chromatin immunoprecipitation. , 2000, Trends in biochemical sciences.

[15]  G. Chenevix-Trench,et al.  Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. , 2000, Carcinogenesis.

[16]  R. Lupu,et al.  HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. , 1999, Cancer research.

[17]  G. Viglietto,et al.  Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation , 1999, Oncogene.

[18]  A. Gazdar,et al.  Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[20]  F. Penault-Llorca,et al.  Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene. , 1999, International journal of oncology.

[21]  C. Croce,et al.  Positive Regulation of the BRCA1 Promoter* , 1999, The Journal of Biological Chemistry.

[22]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[23]  Y. Atomi,et al.  Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. , 1999, Cancer research.

[24]  Y. Bignon,et al.  Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene , 1999, International journal of cancer.

[25]  B. Karlan,et al.  Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas , 1999, Nature Genetics.

[26]  G. Lenoir,et al.  Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region , 1998, Oncogene.

[27]  G. Botti,et al.  Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. , 1998, Cancer research.

[28]  C. Afshari,et al.  Estrogen upregulation of BRCA1 expression with no effect on localization , 1998, Molecular carcinogenesis.

[29]  G. Sourvinos,et al.  Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. , 1998, Biochemical and biophysical research communications.

[30]  C. Clarke,et al.  Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. , 1998, Cancer genetics and cytogenetics.

[31]  A. Fusco,et al.  Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. , 1998, Cancer research.

[32]  A. Dobrovic,et al.  Methylation of the BRCA1 gene in sporadic breast cancer. , 1997, Cancer research.

[33]  H. Ruffner,et al.  BRCA1 is a cell cycle-regulated nuclear phosphoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[35]  F. Couch,et al.  Localization of BRCA1 and a splice variant identifies the nuclear localization signal , 1997, Molecular and cellular biology.

[36]  A. Simeone,et al.  High level expression of the HMGI (Y) gene during embryonic development. , 1996, Oncogene.

[37]  H. Nguyen,et al.  Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[38]  A. Berchuck,et al.  BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[39]  G. Viglietto,et al.  Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. , 1996, Cancer research.

[40]  H. Nguyen,et al.  Hormone-dependent regulation of BRCA1 in human breast cancer cells. , 1995, Cancer research.

[41]  Junzhe Xu,et al.  The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues , 1995, Nature Genetics.

[42]  Xianjin Zhou,et al.  Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C , 1995, Nature.

[43]  G. Chiappetta,et al.  The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. , 1995, Oncogene.

[44]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[45]  M. Santoro,et al.  Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells , 1995, Molecular and cellular biology.

[46]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[47]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[48]  H. G. van der Poel,et al.  Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. , 1993, Cancer research.

[49]  R. Reeves,et al.  Elevated high mobility group-I(Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells. , 1993, Cancer research.

[50]  J. Broach,et al.  Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. , 1993, Genes & development.

[51]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[52]  G. Viglietto,et al.  High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases , 2001, International journal of cancer.

[53]  L. Bennett,et al.  Sequence analysis of the rat Brca1 homolog and its promoter region , 1999, Mammalian Genome.